Logo image of PLX

PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Fundamental Analysis

NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD

2.55  -0.06 (-2.3%)

After market: 2.5502 +0 (+0.01%)

Fundamental Rating

5

PLX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and the financial health of PLX get a neutral evaluation. Nothing too spectacular is happening here. PLX is valued quite cheap, while showing a decent growth score. This is a good combination! This makes PLX very considerable for value investing!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

In the past year PLX was profitable.
In the past year PLX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: PLX reported negative net income in multiple years.
In the past 5 years PLX reported 4 times negative operating cash flow.
PLX Yearly Net Income VS EBIT VS OCF VS FCFPLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

With an excellent Return On Assets value of 3.99%, PLX belongs to the best of the industry, outperforming 93.31% of the companies in the same industry.
With an excellent Return On Equity value of 6.79%, PLX belongs to the best of the industry, outperforming 93.84% of the companies in the same industry.
The Return On Invested Capital of PLX (6.87%) is better than 94.54% of its industry peers.
Industry RankSector Rank
ROA 3.99%
ROE 6.79%
ROIC 6.87%
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLX Yearly ROA, ROE, ROICPLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

PLX has a better Profit Margin (5.49%) than 92.78% of its industry peers.
Looking at the Operating Margin, with a value of 7.34%, PLX belongs to the top of the industry, outperforming 93.66% of the companies in the same industry.
The Gross Margin of PLX (54.46%) is better than 76.76% of its industry peers.
PLX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 7.34%
PM (TTM) 5.49%
GM 54.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
PLX Yearly Profit, Operating, Gross MarginsPLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PLX is destroying value.
PLX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PLX has been increased compared to 5 years ago.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PLX Yearly Shares OutstandingPLX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLX Yearly Total Debt VS Total AssetsPLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.70, we must say that PLX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.70, PLX perfoms like the industry average, outperforming 56.51% of the companies in the same industry.
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -1.7
ROIC/WACC0.65
WACC10.56%
PLX Yearly LT Debt VS Equity VS FCFPLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

PLX has a Current Ratio of 2.34. This indicates that PLX is financially healthy and has no problem in meeting its short term obligations.
PLX has a worse Current ratio (2.34) than 72.01% of its industry peers.
PLX has a Quick Ratio of 1.52. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of PLX (1.52) is worse than 80.46% of its industry peers.
Industry RankSector Rank
Current Ratio 2.34
Quick Ratio 1.52
PLX Yearly Current Assets VS Current LiabilitesPLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

4

3. Growth

3.1 Past

The earnings per share for PLX have decreased strongly by -40.00% in the last year.
PLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.48%.
PLX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.48% yearly.
EPS 1Y (TTM)-40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%228.57%
Revenue 1Y (TTM)-18.48%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%73.74%

3.2 Future

Based on estimates for the next years, PLX will show a very strong growth in Earnings Per Share. The EPS will grow by 431.79% on average per year.
The Revenue is expected to grow by 59.52% on average over the next years. This is a very strong growth
EPS Next Y943.67%
EPS Next 2Y431.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year63.84%
Revenue Next 2Y59.52%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PLX Yearly Revenue VS EstimatesPLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
PLX Yearly EPS VS EstimatesPLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4 6

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 85.00, which means the current valuation is very expensive for PLX.
PLX's Price/Earnings ratio is rather cheap when compared to the industry. PLX is cheaper than 92.25% of the companies in the same industry.
PLX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.29.
With a Price/Forward Earnings ratio of 8.14, the valuation of PLX can be described as very reasonable.
Based on the Price/Forward Earnings ratio, PLX is valued cheaper than 97.36% of the companies in the same industry.
PLX is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.32, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 85
Fwd PE 8.14
PLX Price Earnings VS Forward Price EarningsPLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

PLX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PLX is cheaper than 93.84% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PLX indicates a rather cheap valuation: PLX is cheaper than 94.72% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 26.92
EV/EBITDA 35.22
PLX Per share dataPLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6

4.3 Compensation for Growth

PLX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PLX's earnings are expected to grow with 431.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y431.79%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for PLX!.
Industry RankSector Rank
Dividend Yield N/A

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (4/21/2025, 4:36:01 PM)

After market: 2.5502 +0 (+0.01%)

2.55

-0.06 (-2.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17 2025-03-17/bmo
Earnings (Next)05-09 2025-05-09
Inst Owners6.74%
Inst Owner Change0%
Ins Owners7.79%
Ins Owner Change0%
Market Cap198.98M
Analysts80
Price Target14.79 (480%)
Short Float %8.03%
Short Ratio7.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.78%
Min EPS beat(2)-25.74%
Max EPS beat(2)27.3%
EPS beat(4)1
Avg EPS beat(4)-111%
Min EPS beat(4)-248.51%
Max EPS beat(4)27.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.77%
Min Revenue beat(2)-3.82%
Max Revenue beat(2)9.37%
Revenue beat(4)2
Avg Revenue beat(4)-11.84%
Min Revenue beat(4)-59.64%
Max Revenue beat(4)9.37%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.59%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.87%
Valuation
Industry RankSector Rank
PE 85
Fwd PE 8.14
P/S 3.73
P/FCF 26.92
P/OCF 22.94
P/B 4.6
P/tB 4.6
EV/EBITDA 35.22
EPS(TTM)0.03
EY1.18%
EPS(NY)0.31
Fwd EY12.28%
FCF(TTM)0.09
FCFY3.72%
OCF(TTM)0.11
OCFY4.36%
SpS0.68
BVpS0.55
TBVpS0.55
PEG (NY)0.09
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.99%
ROE 6.79%
ROCE 8.2%
ROIC 6.87%
ROICexc 11.71%
ROICexgc 11.71%
OM 7.34%
PM (TTM) 5.49%
GM 54.46%
FCFM 13.84%
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score5
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 98.31%
Cap/Sales 2.4%
Interest Coverage 2.56
Cash Conversion 166.14%
Profit Quality 252.12%
Current Ratio 2.34
Quick Ratio 1.52
Altman-Z -1.7
F-Score5
WACC10.56%
ROIC/WACC0.65
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%228.57%
EPS Next Y943.67%
EPS Next 2Y431.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.48%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%73.74%
Revenue Next Year63.84%
Revenue Next 2Y59.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y399.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y758.12%
OCF growth 3YN/A
OCF growth 5YN/A